SAMPRE NUTRITIONS LIMITED

CIN: L15499TG1991PLC013515

Date: 14 February 2025

To
The Corporate Relationship Department,
BSE Limited
P.J Towers, 1st Floor,
Dalal Street,
Mumbai – 400001, MH

Subject: Integrated Filing (Financial) for the third quarter and nine months ended 31 December 2024
Ref: BSE Script Code: 530617

Sir / Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December 2024 read with BSE Circular No. 20250102-4 dated 2 January 2025, please find enclosed herewith the Integrated Filing (Financial) for the quarter ended 31 December 2024.

Kindly take the same on record,

Sincerely,

For Sampre Nutritions Limited

BRAHMA GURBANI
Digitally signed by BRAHMA GURBANI
Date: 2025.02.14 17:11:43 +05'30'

Brahma Gurbani
(DIN: 00318180)
Managing Director

Enclosed: *As Above*

Regd. Off & Works: Unit-1: Plot No. 133, I.E, Medchal - 501401. Telangana, India. **Ph:** +91-8418-222428
Unit-2: Plot No. 127, 128, Royes Building, I.E. Medchal, Malkajgiri - 501401.Telangana.
e-mail: gurbani@gurbanigroup.in, bkgurbani@gurbanigroup.in, www.gurbanigroup.in

A. Financial Results
Enclosed

B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutional Placement, etc.
Enclosed

C. Format For Disclosing Outstanding Default On Loans And Debt Securities
Not applicable as no default

D. Format for Disclosure of Related Party Transactions (applicable only for Half-Year filings i.e., 2nd and 4th quarter):
Not Applicable

E. Statement of Impact of Audit Qualifications (for Audit Report with Modified Opinion) submitted along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter):
Not Applicable

For Sampre Nutritions Limited

BRAHMA GURBANI
Digitally signed by BRAHMA GURBANI
Date: 2025.02.14 17:12:00 +05'30'

Brahma Gurbani
(DIN: 00318180)
Managing Director

SAMPRE NUTRITIONS LIMITED

SAMPRE NUTRITIONS LIMITED
Registered Office: Plot No.133, Industrial Estate, Medchal – 501 401.
Website: www.sampreltd.com;Email: gurbani@gurbanigroup.in
STATEMENT OF STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31st DECEMBER, 2024
CIN: L15499TG1991PLC013515

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended on			Nine Months ended on		Year ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	**Income from Operations**						
	(a) Revenue from operations	557.80	726.88	699.25	1735.89	2038.28	2514.68
	(b) Other Income	4.38	0.00	0.29	6.91	3.03	11.81
	Total Revenue (1)	**562.18**	**726.88**	**699.54**	**1,742.80**	**2,041.31**	**2,526.49**
2	**Expenses:**						
	(a) Cost of Materials Consumed	130.42	173.30	261.78	349.67	902.87	953.40
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employees benefits expense	253.22	268.27	244.47	675.75	650.85	775.15
	(e) Finance costs	58.57	44.63	46.94	148.60	144.13	192.06
	(f) Depreciation and amortisation expenses	43.52	43.52	30.57	130.56	91.64	183.29
	(g) Manufacturing expenses						
	(h) Research & Development expenses						
	(i) Other Expenditure	130.17	184.71	95.89	454.85	275.80	366.06
	Total Expenses (2)	**615.90**	**714.43**	**679.65**	**1,759.43**	**2,065.29**	**2,469.96**
3	**Profit/Loss before exceptional and extraordinary items and tax (1-2)**	**-53.72**	**12.45**	**19.89**	**-16.63**	**-23.98**	**56.53**
4	Exceptional Items						
5	**Profit/Loss before extraordinary items and tax (3-4)**	**-53.72**	**12.45**	**19.89**	**-16.63**	**-23.98**	**56.53**
6	**Tax Expenses:**						
	(1). Current tax						
	(2). Deferred tax						
7	**Profit/Loss for the period from continuing operations (5-6)**	**-53.72**	**12.45**	**19.89**	**-16.63**	**-23.98**	**56.53**
8	Profit/Loss from discontinued operations						
9	Tax expenses of discontinued operations						
10	**Profit/Loss from discontinued operations after tax (8-9)**						
11	**Profit/Loss for the period (7+10)**	**-53.72**	**12.45**	**19.89**	**-16.63**	**-23.98**	**56.53**
12	**Other Comprehensive Income**						
	A (1). Items that will not be reclassified to profit or loss						
	(2). Incometax relating to items that will not be reclassified to profit or loss						
	B (1). Items that will be reclassified to profit or loss						
	(2). Incometax relating to items that will be reclassified to profit or loss						
13	**Total Comprehensive Income for the period (11+12) (comprising Profit/Loss) and other comprehensive income for the period**	**-53.72**	**12.45**	**19.89**	**-16.63**	**-23.98**	**56.53**
14	**Paid Up Equity Capital (Face value of Rs.10/- each Number)**	**179.61**	**72.70**	**68.70**	**179.61**	**68.70**	**68.70**
15	**Reserves excluding Revaluation Reserves as per balance sheet of Previous accounting year**						
16	**Earning Per Equity Share (EPS) for continuing operations**						
	A) Basic	(0.30)	0.14	0.29	(0.09)	(0.35)	0.43
	B) Diluted	(0.29)	0.14	0.21	(0.09)	(0.25)	0.33

Notes:

1. The above results were approved by the Board of Directors of the Company at its meeting held on 13th February, 2025 and the statutory auditors of the company have carried out limited review of the same.
2. The Company is having Subsidiary, Joint Venture and Associate, hence consolidated results are published.
3. The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
4. During the year the Company has issued 100 Bonds (FCCB) at 15% Discount and received amount against Foreign Currency Convertible Bonds (FCCB) of 100 Bonds for USD 10.00 Million (Ten Millions United states Dollars). During the Quarter Out of 100 Bonds 64 Bonds were converted fullly against Equity shares of 89,91,711 shares. Other bonds are yet to be converted.
5. There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor compalints during the quarter.
6. Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place : Hyderabad
Date : 13.02.2025

Sampre Nutritions Ltd * Plot No. 133 I.E. Medchal * Medchal-Malkajgiri Dist

For and on behalf of the Board
Sampre Nutritions Limited

Managing Director
Brahma Gurbani
DIN : 00318180

N G RAO & ASSOCIATES
CHARTERED ACCOUNTANTS

☎ Off: +91-40-4240 8813
Mobile : 98480 18791
98491 35573
95421 87777

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
SAMPRE NUTRITIONS LIMITED

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SAMPRE NUTRITIONS LIMITED** ("the Company"), for the quarter and nine months ended December 31st 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G Rao & Associates
Chartered Accountants
Firm Registration Number: 009399S

HYDERABAD FRN: 009399S

CA. G. Nageswara Rao
Partner
Membership No. 207300
UDIN: 25207300BMIJUV4036

Place: Hyderabad
Date: 13-02-2025

H.No. 6-3-1186/A/6, (New No. 325), 2nd Floor, Chinna Balreddy Building, Adjacent Lane to ITC Kakatiya Hotel, Begumpet, Hyderabad-500 016.

Flat No.203, D.No. 48-10-20, Veeramachaneni Building, New Govt Hospital Road, Gunadala, Vijayawada - 520 004

H.No. 8-22-5/1, FF3, Neeladri Towers, Pattabi Street, Gandhi Nagar, Kakinada - 533 004.

Flat No.104, Sai Thirumala Enclave, Lalitha Nagar, Behind Lalitha Temple, Visakhapatnam-530016

Email : nageswararaog207@gmail.com / nageswararaog@rediffmail.com

SAMPRE NUTRITIONS LIMITED

SAMPRE NUTRITIONS LIMITED
Registered Office: Plot No.133, Industrial Estate, Medchal – 501 401.
Website: www.sampreltd.com;Email: gurbani@gurbanigroup.in
CONSOLIDATED STATEMENT OF UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31st DECEMBER, 2024
CIN: L15499TG1991PLC013515

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended on			Nine Months ended on		Year ended
		31.12.2024 (un audited)	30.09.2024 (un audited)	31.12.2023 (Audited)	31.12.2024 (un audited)	31.12.2023 (Audited)	31.03.2024 (Audited)
1	**Income from Operations**						
	(a) Revenue from operations	557.80	726.88	-	1735.89	-	2514.68
	(b) Other Income	4.38	0.00	-	6.91	-	11.81
	Total Revenue (1)	**562.18**	**726.88**	-	**1742.80**	-	**2526.49**
2	**Expenses:**						
	(a) Cost of Materials Consumed	130.42	173.30	-	349.67	-	953.39
	(b) Purchase of stock-in-trade	0.00	0.00	-	0.00	-	0.00
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	-	0.00	-	0.00
	(d) Employees benefits expense	253.22	268.27	-	675.75	-	775.15
	(e) Finance costs	58.57	44.63	-	148.60	-	192.24
	(f) Depreciation and amortisation expenses	43.52	43.52	-	130.56	-	183.29
	(g) Manufacturing expenses						
	(h) Research & Development expenses						
	(i) Other Expenditure	130.64	184.71	-	470.07	-	373.66
	Total Expenses (2)	**616.37**	**714.43**	-	**1774.65**	-	**2,477.73**
3	**Profit/Loss before exceptional and extraordinary items and tax (1-2)**	**-54.19**	**12.45**	-	**-31.85**	-	**48.76**
4	Exceptional Items						
5	**Profit/Loss before extraordinary items and tax (3-4)**	**-54.19**	**12.45**	-	**-31.85**	-	**48.76**
6	**Tax Expenses:**						
	(1). Current tax						
	(2). Deferred tax						25.58
7	**Profit/Loss for the period from continuing operations (5-6)**	**(54.19)**	**12.45**	-	**-31.85**	-	**23.18**
8	Profit/Loss from discontinued operations						
9	Tax expenses of discontinued operations						
10	**Profit/Loss from discontinued operations after tax (8-9)**						
11	**Profit/Loss for the period (7+10)**	**-54.19**	**12.45**	-	**-31.85**	-	**23.18**
12	**Other Comprehensive Income**						
	A (1). Items that will not be reclassified to profit or loss						
	(2). Incometax relating to items that will not be reclassified to profit or loss						
	B (1). Items that will be reclassified to profit or loss						
	(2). Incometax relating to items that will be reclassified to profit or loss						
13	**Total Comprehensive Income for the period (11+12) (comprising Profit/Loss) and other comprehensive income for the period**	**-54.19**	**12.45**	-	**-31.85**	-	**23.18**
14	**Paid Up Equity Capital (Face value of Rs.10/- each)**	**179.61**	**72.70**	-	**179.61**	-	**68.70**
15	**Reserves excluding Revaluation Reserves as per balance sheet of Previous accounting year**						
16	**Earning Per Equity Share (EPS) for continuing operations**						
	A) Basic	**(0.30)**	**0.14**	-	**(0.18)**	-	**0.32**
	B) Diluted						
17	**Earning Per Equity Share (EPS) for discontinuing operations**						
	A) Basic						
	B) Diluted						
18	**Earning Per Equity Share (EPS) for discontinuing & continuing operations**						
	A) Basic	**(0.30)**	**0.14**	-	**(0.18)**	-	**0.32**
	B) Diluted	(0.29)	0.14	-	(0.17)	-	0.24

Notes:

1. The above results were approved by the Board of Directors of the Company at its meeting held on 13th February, 2025 and the statutory auditors of the company have carried out limited review of the same.
2. The Company is having Subsidiary, called **Sampre Nutritions FZCO, UAE,** hence consolidated results are published.
3. The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
4. During the year the Company has issued 100 Bonds (FCCB) at 15% Discount and received amount against Foreign Currency Convertible Bonds (FCCB) of 100 Bonds for USD 10.00 Million (Ten Millions United states Dollars). During the Quarter Out of 100 Bonds 64 Bonds were converted fullly against Equity shares of 89,91,711 shares. Other bonds are yet to be converted.
5. There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor compalints during the quarter.
6. Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Sampre Nutritions Ltd * Plot No.133 I.E. Medchal * Medchal-Malkajgiri Dist

For and on behalf of the Board
Sampre Nutritions Limited

Managing Director
Brahma Gurbani
DIN : 00318180

Place : Hyderabad
Date : 13.02.2025

N G RAO & ASSOCIATES
CHARTERED ACCOUNTANTS

☎ Off: +91-40-4240 8813
Mobile : 98480 18791
98491 35573
95421 87777

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
M/s. SAMPRE NUTRITIONS LIMITED

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s. SAMPRE NUTRITIONS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended 31st December,2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the following entities:

S.No.	Name of the Entity
1	M/S Sampre Nutritions FZCO (Subsidiary)

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attrition that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

N G RAO & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ HYDERABAD FRN: 009399S

H.No. 6-3-1186/A/6, (New No. 325), 2nd Floor, Chinna Balreddy Building, Adjacent Lane to ITC Kakatiya Hotel, Begumpet, Hyderabad-500 016.

Flat No.203, D.No. 48-10-20, Veeramachaneni Building, New Govt Hospital Road, Gunadala, Vijayawada - 520 004

H.No. 8-22-5/1, FF3, Neeladri Towers, Pattabi Street, Gandhi Nagar, Kakinada - 533 004.

Flat No.104, Sai Thirumala Enclave, Lalitha Nagar, Behind Lalitha Temple, Visakhapatnam-530016

Email : nageswararaog207@gmail.com / nageswararaog@rediffmail.com

We did not review the interim financial information of subsidiary company which are included in the consolidated quarterly and nine months ended unaudited financial results, whose interim financial results include total revenue Rs.0.00 Lakhs and Rs.0.00 for the respective quarter and nine months ended 31st December 2024, in respect of 1 subsidiary, which have been reviewed by other auditors, which financial statements, other financial information and auditor's reports have been furnished to us by the management. Our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries is based solely on the reports of such other auditors.

For N G Rao & Associates
Chartered Accountants
Firm Registration Number: 009399S



CA. G. Nageswara Rao
Partner
Membership No. 207300
UDIN: 25207300BMIJUW9155

Place: Hyderabad
Date: 13-02-2025

B. Statement of deviation/ variation in use of Issue proceeds:

Sl. No.	Particulars	Details
1.	Name of the Listed Entity	Sampre Nutritions Limited
2.	Mode of Fund Raising	Preferential Issue
3.	Type of Instrument	Foreign Currency Convertible Bonds
4.	Date of Raising Funds	28 June 2024*
5.	Amount Raised	INR 53,80,64,000
6.	Report filed for quarter ended	31 December 2024
7.	Is there a deviation / variation in use of funds raised?	Not applicable
8.	Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document?	~~Yes /~~ No
9.	If yes, details of the approval so required?	Not applicable
10.	Date of approval	23 December 2022
11.	Explanation for the deviation / variation	Not applicable
12.	Comments of the audit committee after review	None
13.	Comments of the auditors, if any	None
14.	Objects for which funds have been raised and where there has been a deviation / variation, in the following table:	

Original Object	Modified Object, if any	Original allocation	Modified allocation, if any	Funds utilized	Amount of deviation / variation for the quarter according to applicable object	Remarks, if any
General corporate purposes	N.A.	INR 53.80 Crores	N.A.	Nil	Nil	N.A.

Deviation could mean:

a. Deviation in the objects or purposes for which the funds have been raised.

b. Deviation in the amount of funds actually utilised as against what was originally

	disclosed. c. Change in terms of a contract referred to in the fund-raising document, i.e. prospectus, letter of offer, etc.

* On 14 October 2024, 64 FCCBs have been converted into 8991711 fully paid-up equity shares.

For Sampre Nutritions Limited

BRAHMA GURBANI
Digitally signed by BRAHMA GURBANI
Date: 2025.02.14 17:12:22 +05'30'

Brahma Gurbani
(DIN: 00318180)
Managing Director